We analyzed the incidence and risk factors for chronic graft-versus-host disease (GVHD) in 265 children undergoing allogeneic stem cell transplantation (SCT) who survived longer than 3 months post SCT. Patients transplanted from HLA-mismatched related donors and matched unrelated donors were included. Fifty-five patients developed chronic GVHD between 1 and 25 months after SCT, and the 5-year cumurative incidence of chronic GVHD was 22%. By multivariate analysis, acute GVHD (P = 0.004), malignant disease (P = 0.004), recipient age (у10 years) (P = 0.01) and a female donor to male recipient (P = 0.035) were significant risk factors for chronic GVHD. When acute GVHD was excluded from the multivariate analysis, malignant disease (P = 0.002) and older recipient age (P = 0.007) were identified. The incidence of chronic GVHD in this childhood study was lower than that observed in adults, and recipient age was an important factor in childhood SCT. The high incidence associated with malignant disease may be affected by changes in GVHD prophylaxis in order to ensure graft-versus-tumor effects. Bone Marrow Transplantation (2001) 27, 727-730.
Chronic graft-versus-host disease (GVHD) is a major complication following allogeneic stem cell transplantation (SCT). More than one-third of long-term survivors are affected by chronic GVHD. 1 Risk factors for chronic GVHD have been examined in many studies, and acute GVHD is recognized as an important predictor of chronic GVHD. [2] [3] [4] [5] [6] [7] Because older recipient age is also recognized as a risk factor for chronic GVHD, [3] [4] [5] [6] [7] a lower incidence of chronic GVHD may be expected in children. There is also a possibility that risk factors for chronic GVHD in children differ from those in adults. However, very few studies have focused on chronic GVHD in children. Therefore, to evalu- ate the incidence and risk factors for chronic GVHD in children, we reviewed the records of 265 children who underwent allogeneic SCT and survived longer than 3 months post-SCT.
Patients and methods

Patients and donors
Three hundred and nine children underwent allogeneic SCT at Nagoya University Hospital and Japanese Red Cross Nagoya First Hospital between April 1982 and December 1998. Among these, 265 survived longer than 3 months post SCT and were included in this study. Patient characteristics and donor relationships are summarized in Table 1 . 
Diagnosis of chronic GVHD
The diagnosis of chronic GVHD was made on the basis of clinical symptoms and histopathologic findings of the skin or oral mucosa according to criteria previously described. 8, 9 The grading of chronic GVHD as limited or extensive was used as previously described.
8,9
Statistical analysis
The cumulative incidence of chronic GVHD was calculated using the Kaplan-Meier method. Death and second SCT were censored observations if chronic GVHD was not present. Data were analyzed as of 1 October, 1999. To examine risk factors for chronic GVHD, univariate and multivariate analyses were performed using the Cox regression model. Factors associated with chronic GVHD in univariate analysis with P Ͻ 0.2 were tested in using stepwise multivariate analysis. P values Ͻ0.05 were considered to indicate statistical significance.
Results
Among 265 patients who survived longer than 3 months post-SCT, 55 developed chronic GVHD between 1 and 25 months (median 3 months) after SCT. The cumulative incidence of chronic GVHD at 5 years was 22% (Figure 1 ). Thirty-six were boys and 19 were girls. The median age at onset was 9 years (range, 0-15 years). Twenty-four patients had prior grade 1 to 4 acute GVHD: progressive type (n = (%)  100  90  80  70  60  50  40  30  20  10  0  5  4  3  2  1  0 Years after transplantation Probability of chronic GVHD 22% (n = 265) Figure 1 Probability and time to chronic GVHD in all patients (n = 265). The cumulative incidence of chronic GVHD at 5 years was 22%.
8) and quiescent type (n = 16). De novo onset occurred in 31 patients. Skin (n = 31) and oral mucosa (n = 34) were the major organs affected by chronic GVHD. Thirty-two patients had extensive, and 23 had limited chronic GVHD.
Risk factors for chronic GVHD: univariate analysis
The factors examined for an association with chronic GVHD by univariate analysis are shown in Table 2 . Recipient age was identified as a significant risk factor for chronic GVHD (P = 0.015); the cumulative incidence in older patients (у10 years) was higher than that in younger patients (31% and 17%, respectively). Recipient gender and donor gender were not significant factors, but the donorrecipient gender relationship was significant: a female donor to male recipient significantly increased the risk of developing chronic GVHD (P = 0.024). HLA mismatching was not identified as a risk factor despite several combinations being examined. The risk of chronic GVHD in patients with malignant disease was significantly increased (P Ͻ 0.001). Both TBI and MEL were identified as significant risk factors for chronic GVHD (P = 0.034 and 0.007, respectively). CY was associated with a decreased risk of chronic GVHD (P = 0.024), but ATG was not associated with decreased risk (P = 0.29). GVHD prophylaxis did not affect the incidence of chronic GVHD. Acute GVHD was a significant predictor of chronic GVHD: both grade 1 to 4 (P Ͻ 0.001) and grade 2 to 4 (P = 0.022).
Risk factors for chronic GVHD: multivariate analysis
Four factors were identified as multivariate risk factors for chronic GVHD: acute GVHD grade 1 to 4 (P = 0.004), malignant disease (P = 0.004), recipient age у10 years (P = 0.01) and a female donor to male recipient (P = 0.035). When acute GVHD was excluded from the multivariate analysis, only malignant disease and recipient age remained (P = 0.002 and 0.007, respectively) ( Table 3) .
Discussion
Recipient age has been identified as one of the major risk factors for chronic GVHD in several studies, [3] [4] [5] [6] [7] and younger patients are considered to have a decreased risk of chronic GVHD. The incidence of chronic GVHD is generally estimated at 40-50%, [2] [3] [4] [5] [6] [7] and several factors, including acute GVHD, recipient age and donor-recipient gender relationship, have been shown to increase the risk of chronic GVHD. However, these findings are based on adult patients and only a few on childhood patients. In our retrospective study, we reviewed 265 children at risk for chronic GVHD.
In our childhood study, the incidence of chronic GVHD was 22%, lower than that observed in adult studies. This result would be expected from previous studies in which increasing recipient age was associated with a higher risk of chronic GVHD. Locatelli et al 10 reported a similarly low Bone Marrow Transplantation incidence (24%) of chronic GVHD in children. Eisner et al 11 also reported a low incidence (29%), and they also found that recipient age was an important risk factor in pediatric patients, although this was not confirmed by multivariate analysis. In our study, older patients (у10 years) had an increased risk of chronic GVHD by multivariate analysis. Recipient age is therefore an important risk factor for chronic GVHD in children.
In addition to recipient age, acute GVHD, malignant disease, and a female donor to male recipient were identified as significant risk factors for chronic GVHD by multivariate analysis. Acute GVHD cannot be taken into consideration in the planning of SCT in order to predict the development of chronic GVHD because it is a post-transplant event. Therefore, we performed a multivariate analysis excluding acute GVHD as a covariate. In this analysis, older recipient age and malignant disease remained significant factors, but female donor to male recipient risk was not significant. In several previous reports, a female donor to male recipient was recognized as a risk factor for chronic GVHD, based on alloimmunization of the female donor. 5, 7 In childhood SCT, however, HLA-identical siblings are rarely alloimmunized, and alloimmunized female donors would be considered non-identical. Therefore, it is unclear whether alloimmunization affects the development of chronic GVHD in childhood SCT.
Carlens et al 7 reported that chronic myelogenous leukemia was a significant risk factor for chronic GVHD, but rarely have underlying diagnoses been associated with chronic GVHD. In our study, malignant disease was identified as a significant risk factor for chronic GVHD by multivariate analysis. In non-malignant disease, chronic GVHD is an unambiguous complication which impairs the quality of life of affected patients. By contrast, chronic GVHD demonstrates graft-versus-tumor effects which reduce the risk of relapse in malignant disease. [12] [13] [14] [15] [16] We did not use CyA in most patients with malignant disease transplanted from an HLA-identical sibling, while CyA was used in all patients with non-malignant disease. Furthermore, blood concentrations of CyA were lower, and tapering of CyA was more rapid in patients with malignant disease who were transplanted from an alternative donor. The combination of these factors may be strongly associated with a higher incidence of chronic GVHD in patients with malignant disease.
In summary, the 5-year cumulative incidence of chronic GVHD in our 265 children was 22%, lower than that observed in adult studies. Malignant disease and older recipient age were identified as risk factors for chronic GVHD when acute GVHD was excluded from multivariate analysis. The former may be explained by the specific methods of GVHD prophylaxis to enhance graft-versustumor effects.
